Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
Authors
Keywords
-
Journal
Journal of Diabetes Investigation
Volume 5, Issue 4, Pages 382-391
Publisher
Wiley
Online
2013-11-28
DOI
10.1111/jdi.12156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
- (2013) Stephan A. Veltkamp et al. CLINICAL DRUG INVESTIGATION
- Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?
- (2012) J. Liu et al. DIABETES
- Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial
- (2012) K. Kaku et al. DIABETES OBESITY & METABOLISM
- Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^|^ndash;Nicotinamide-Induced Mildly Diabetic Mice
- (2012) Atsuo Tahara et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values
- (2012) Atsunori Kashiwagi et al. Journal of Diabetes Investigation
- Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
- (2011) Sherwyn L. Schwartz et al. Diabetes Technology & Therapeutics
- Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
- (2011) Atsuo Tahara et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Sodium-Glucose Co-Transport Inhibitors
- (2010) Joshua J. Neumiller et al. DRUGS
- Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors
- (2010) Priscilla A. Hollander et al. POSTGRADUATE MEDICINE
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents
- (2009) William N Washburn EXPERT OPINION ON THERAPEUTIC PATENTS
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started